Mark Levis, MD, PhD, weighs in on the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who have failed prior FLT3 TKI therapy.
Evolving treatment considerations for FLT3 mutated AML
Advertisement
[the_ad id="32629"]